Why Did Angelina Jolie Have Both Breasts Removed?
In this article
🎗️ Angelina Jolie and Hereditary Cancer Risk: An Exemplary Awareness Story
Cancer is a complex, multifaceted, genetically based group of diseases affecting millions worldwide. Changes in cellular genetics underlie every cancer. Most are acquired during life, but approximately %10-15 of cancers are hereditary.
Inherited genetic predispositions cause hereditary cancers, making prevention and early diagnosis vitally important. Jolie's public sharing of her experience became an influential worldwide example in raising awareness.
Through her story, this article discusses hereditary breast and ovarian risks, genetic testing and current scientific approaches.
🧬 Jolie's Courageous Decision: An Inheritance from Her Mother
Angelina Joliebegan investigating her risk after losing her mother to ovarian cancer at 56. Testing revealed a pathogenic mutation in BRCA1 .
🔺 Risk Levels: The BRCA1 mutation raised Jolie's breast cancer risk to %87, ovarian cancer risk to %50 .
Faced with this risk, she underwent:
- Bilateral prophylactic mastectomy .
- After surgery, breast reconstruction reduced aesthetic concerns.
- Later, she underwent prophylactic oophorectomy and entered menopause.
Sharing the difficult journey openly inspired genetically at-risk women and highlighted risk management, early diagnosis and individual decisions.
🔍 Hereditary Breast and Ovarian Cancer: Genes' Role
%5-10 of cancers are hereditary and the commonest inherited syndromes involve BRCA1 and BRCA2 mutations.
🧬 BRCA Gene Functions: Normally tumor suppressors, BRCA1/2 repair DNA damage. Mutations disrupt this, potentially allowing uncontrolled growth and cancer.
📊 Increased Cancer Risk:
- General population breast cancer risk: %12
- In BRCA carriers: %45-%85
- Ovarian risk: Generally %1-2, with BRCA %20-%60
BRCA mutations also increase risks of prostate, pancreatic and melanoma and other cancers.
🔍 Options for At-Risk Individuals: Beyond Surgery
Jolie's preventive surgery is not the only optionfor high-risk individuals. Current medicine offers various approaches to genetic risk management:
1. 📅 Intensified Screening and Surveillance
For Breast Cancer: Annual mammography, breast MRI and clinical examination can begin younger and occur more frequently.
For Ovarian Cancer: Gynecological examination, transvaginal ultrasound and CA-125 blood testing are recommended, though early detection is harder than in breast cancer.
2. 💊 Chemoprevention (Drug-Based Risk Reduction)
Tamoxifen and Raloxifene and other SERMs, plus aromatase inhibitors may reduce postmenopausal breast cancer risk. Benefits and possible effects should be assessed against the individual risk profile .
3. 🏥 Prophylactic Surgery (Risk-Reducing Surgery)
Prophylactic Mastectomy: Removing both breasts can reduce risk by %90-95. Modern reconstruction techniques can address aesthetic concerns.
Prophylactic Salpingo-oophorectomy: Removing ovaries and fallopian tubes reduces ovarian risk by %80-90 and indirectly breast risk, but may cause early menopause .
🤝 Decision-Making and Support
- Genetic Counseling: Before and after testing, counseling supports informed decisions.
- Multidisciplinary Approach: Collaboration among oncologists, surgeons, geneticists and psychologists offers optimal management.
- Psychological Support: The process may cause stress and anxiety, which support eases.
- Personal Preferences: Final choices should fit lifestyle, values and expectations.
📌 Conclusion: Shaping the Future with Informed Choices
Jolie's story symbolizes the power of preventive steps for genetically predisposed people. Access to information and testing is easier; at-risk individuals can rewrite their destiny.
Every story differs. What matters is proceeding with a scientific, personalized and holistic approach. Beyond treating cancer, prevention and early detection are among the strongest steps in the health struggle.
Sources
2. Kauff ND, Domchek SM, Friebel TM, et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol. 2008;26(8):1331-1337. doi:10.1200/JCO.2007.13.9626
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.